510(k) Report

510(k) · Cleared

Cleared

Nalu Neurostimulation System

K203547510(k) TraditionalCleared Mar 25, 2021111-day reviewClass II21 CFR 882.5880

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Boston Scientific Neuromodulation · GZB Stimulator, Spinal-Cord, Implanted (Pain Relief)

Cleared on Mar 25, 2021 as substantially equivalent to K201618 (Boston Scientific Neuromodulation, 2020) after a 111-day review. Its family tree reaches back 8 generations to 1988. 2 later devices descend from it.

Decided
Mar 25, 2021
Review
111 days
Class
Class II
Product code
GZB
Recalls
None
Predicates
1

Its longest line of descent runs back 8 generations to K883780 (1988). 10 ancestors in all. 2 later devices descend from it, 1 citing it directly.

  1. Root · 8 generations backK883780 Xtrel, Model Number 3425Medtronic Vascular · 1988
  2. 7 generations backK141399 Freedom Spinal Cord Stimulator (SCS) SystemStimwave Technologies Incorporated · 2014
  3. 6 generations backK150517 Freedom Spinal Cord Stimulator SystemStimwave Technologies Incorporated · 2015
  4. 5 generations backK160600 Freedom Spinal Cord Stimulator SystemStimwave Technologies Incorporated · 2016
  5. 4 generations backK162161 Receiver Kit, Trial Kit, Spare Lead Kit, Sterile Revision Kit…Stimwave Technologies Incorporated · 2016
  6. 3 generations backK170141 Receiver Kit, Trial Kit, Spare Lead Kit, Sterile Revision Kit…Stimwave Technologies Incorporated · 2017
  7. 2 generations backK183047 Nalu Neurostimulation SystemBoston Scientific Neuromodulation · 2019 · Recalled
  8. 1 generation backK201618 Nalu Neurostimulation SCS systemBoston Scientific Neuromodulation · 2020
  9. This deviceK203547 Nalu Neurostimulation SystemBoston Scientific Neuromodulation · 2021
  10. Descendant · cites it directly · 1 of its ownK221376 Nalu Neurostimulation SystemBoston Scientific Neuromodulation · 2022
  11. Descendant · 2 generations on · 0 of its ownK233801 Nalu Neurostimulation System for Spinal Cord Stimulation; Nalu…Boston Scientific Neuromodulation · 2024 · Recalled

Most influential descendants

Showing 2 of 2 · See all
  • K221376Nalu Neurostimulation SystemBoston Scientific Neuromodulation · 2022 · cites it directly1descendant
  • K233801Nalu Neurostimulation System for Spinal Cord Stimulation; Nalu Neurostimulation System…Boston Scientific Neuromodulation · 2024 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−8K883780Xtrel, Model Number 3425Medtronic Vascular1988—
−7K141399Freedom Spinal Cord Stimulator (SCS) SystemStimwave Technologies Incorporated2014—
−6K150517Freedom Spinal Cord Stimulator SystemStimwave Technologies Incorporated2015—
−5K160600Freedom Spinal Cord Stimulator SystemStimwave Technologies Incorporated2016—
−4K162161Receiver Kit, Trial Kit, Spare Lead Kit, Sterile Revision Kit, Wearable…Stimwave Technologies Incorporated2016—
−3K170141Receiver Kit, Trial Kit, Spare Lead Kit, Sterile Revision Kit, Wearable…Stimwave Technologies Incorporated2017—
−2K183047Nalu Neurostimulation SystemBoston Scientific Neuromodulation20191
−1K201618Nalu Neurostimulation SCS systemBoston Scientific Neuromodulation2020—
0 (this device)K203547Nalu Neurostimulation SystemBoston Scientific Neuromodulation2021—
+1K221376Nalu Neurostimulation SystemBoston Scientific Neuromodulation2022—
+2K233801Nalu Neurostimulation System for Spinal Cord Stimulation; Nalu…Boston Scientific Neuromodulation20241

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199510
200110

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202210
202410
FIG. 1 — Lineage of K203547, 1988–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GZB? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GZB device

  1. #1 K221376 Nalu Neurostimulation Systemscore 8.9 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K201618Nalu Neurostimulation SCS system
Summary page 5
…Division of Neurological and Physical Medicine Devices 3. Predicate and Reference Devices: Predicate Device: Nalu Neurostimulation System (K201618) Reference Devices: Medtronic Xtrel Model 3425 (K883780 and K982902) 4. Device Description The Nalu Neurostimulat…
Boston Scientific Neuromodulation2020—
†K883780Xtrel, Model Number 3425Medtronic Vascular1988—
†K982902Peripheral Nerve StimulationMedtronic Vascular1998—

What descends from it? (2)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K221376Nalu Neurostimulation SystemBoston Scientific Neuromodulation20221

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 33 years and passes through 3 companies; a new generation was cleared every 1.2 years on median.
  • 1 of the 10 ancestors has a recall of any class.
  • Of its descendants, K221376 (Boston Scientific Neuromodulation, 2022) has gone furthest, with 1 descendant of its own.

How does its category compare?

All GZB devices

GZB Stimulator, Spinal-Cord, Implanted (Pain Relief): FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · GZB

1in 2024

2007: 22008: 12009: 32010: 12011: 42012: 22013: 22014: 22015: 22016: 22017: 22018: 12019: 42020: 22021: 12022: 12024: 1
2007high 4 (2011) · low 0 (2023)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GZB

149in 2019

2009: 62 days median2011: 67 days median2019: 149 days median
2007high 149 (2019) · low 62 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GZB

1in 2010

2008: 12010: 12026 (partial year): 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GZB

313in 2025

2007: 2012008: 682009: 592010: 1572011: 4712012: 1,0902013: 4,4282014: 10,8492015: 7,5072016: 4,5562017: 5,5112018: 5,2442019: 6432020: 4662021: 3322022: 2092023: 2362024: 3182025: 313
2007high 10,849 (2014) · low 59 (2009)2025

MAUDE reports naming product code GZB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—0201
20081—168
2009362059
20101—1157
20114670471
20122—01,090
20132—04,428
20142—010,849
20152—07,507
20162—04,556
20172—05,511
20181—05,244
201941490643
20202—0466
20211—0332
20221—0209
20230—0236
20241—0318
20250—0313
20260—1—

What is it indicated for?

For Spinal Cord Stimulation This system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device. For Peripheral Nerve Stimulation This…

Read the full statement (145 words)

For Spinal Cord Stimulation

This system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain.

The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.

For Peripheral Nerve Stimulation

This system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The system is not intended to treat pain in the craniofacial region.

The trial devices are solely used for trial stimulation (no longer than 30 day) to determine efficacy before recommendation for a permanent (long term) device.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K203547: Nalu Neurostimulation System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K203547

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026